GSK plc announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Benlysta, a B-cell inhibiting monoclonal antibody, for the potential treatment of systemic sclerosis. GSK plans to initiate a phase II/III trial of belimumab for systemic sclerosis associated interstitial lung disease, or SSc-ILD, in the first half of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- JMP Securities says older-adult update continues to look encouraging for CureVac
- CureVac announces data in older adults from COVID-19, flu mRNA vaccines
- GSK’s belimumab granted orphan designation as treatment of systemic sclerosis
- Moderna price target raised to $111 from $102 at SVB Securities
- Regenxbio names Curran Simpson as COO